A new class of drug for pulmonary arterial hypertension. Can a Rho-kinase inhibitor break the stagnation in treating it?
Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.
Kazuya
K
Miyagawa
Noriaki
N
Emoto
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006976:Hypertension, Pulmonary; D008168:Lung / Q000098:blood supply*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D054460:rho-Associated Kinases / Q000037:antagonists & inhibitors*
D047428:Protein Kinase Inhibitors; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D054460:rho-Associated Kinases; C049347:fasudil